Australia Has World-Class Research. Now It Needs an Investment Strategy to Match.

Australia may be far from the world's major markets, but its health and medical research has earned international recognition for its excellence. In the 2026 Global Innovation Index, Australia ranked 9th globally for human capital and research. Its ranking of 26th for knowledge and technology outputs points to an opportunity to build on those strengths, particularly by attracting investment that can help bring more Australian discoveries to patients and markets internationally.

Realizing that potential starts with how public investment is structured. The National Health and Medical Research Council largely funds discovery, while the Medical Research Future Fund predominantly focuses on translation. Disbursements from the latter have been capped at about $650 million a year, though the 2026-27 Federal Budget committed to lifting them to $1 billion by 2030-31. That commitment matters, but realizing Australia's full potential may also require faster decisions, a greater appetite for risk, and new sources of capital working alongside the government.

Research investment also spans federal and state governments, universities, institutes, industry, philanthropy, and disease-specific organizations. A recent government review of Australia's research and development system found uncoordinated programs, duplicated effort across jurisdictions, and overlapping grant schemes. Research investment must also account for different community needs.

Comparable economies show what is possible. In the 2026 Global Innovation Index, South Korea and Singapore ranked fourth and fifth overall, with Singapore leading the world for innovation inputs. Both made innovation a national economic priority and backed it with a portfolio approach with both government investment and incentives around R&D. They deliberately created environments where research and industry could collaborate and commercialize, and they maintained the commitment over the long term and at scale. Australia has the research strengths to compete on that stage. With the right predictable investment conditions, it could become a leading destination for global health and medical innovation investment.

Nadia Levin, CEO and Managing Director of Research Australia, the national peak body for health and medical research and innovation, sees the issue from across the whole system. Research Australia represents universities, institutes, industry, funders, and consumers, rather than any single disease or discipline. "This is not a choice between more investment and smarter investment," Levin says. "Australia needs both, and it needs to get far more impact from what it already has."

According to Levin, the system too often asks the government to pick individual projects rather than view investment holistically. In her view, different types of research require different approaches to investment. Public funding is essential for research that improves population health, even when there is no commercial return. It also supports discoveries with commercial potential. But turning those discoveries into products for global markets requires additional capital, expertise, and risk-taking from industry, philanthropy, and private investors.

"The government plays an essential role in supporting population health," Levin says. "Where we need to apply focus for much more significant impact is translation and commercialization, and that is where the other capital needs to step in and be put to work alongside public investment to create economies of scale and drive higher-risk, higher-reward mindsets. Of course, this has to be balanced with prudent stewardship of taxpayers' dollars, but pragmatism must be part of the equation."

In August, Levin called for a blended investment approach that would bring government, private capital, and philanthropy together. Drawing on international models, she believes Australia could create clearer pathways for different investors to contribute according to their objectives, risk appetite, and the outcomes they seek. Government investment would remain essential, while industry and private capital could help promising discoveries progress through translation and commercialization, and philanthropy could support research addressing unmet health needs.

"Australia already produces extraordinary research; what we need to do is be consistent in supporting this research to both outcomes and impact, both clinical and commercial, " she says. "With government, industry and philanthropy investing together, we could turn it into a global innovation advantage."

Levin believes this would also require a whole-of-nation approach. Competition between states can drive ambition, but on the global stage, Australia must present as one front, investing according to each state's strengths rather than replicating the same capabilities everywhere. "Investors don't care which state an idea comes from," she notes. "They care whether Australia is serious." Combined with its position in the Asia-Pacific region, she believes a coordinated approach could make Australia an attractive partner for international investors seeking the next wave of medical breakthroughs.

For Levin, policy settings need stability as well as ambition. Research and development incentives need time to work rather than frequent changes, and long-term investment must outlast short political cycles. She believes leadership should come from the highest levels of government, with a clear national goal that public, private, and philanthropic investors can rally behind. "We are very good at describing the problem," she says. "Now we need to commit to co-designing and applying the solution."

Advances in AI, quantum technology, and digital health may mark the biggest shift since the Industrial Revolution, and Levin warns that nations that hesitate risk falling to the back of the queue. Australia has already given the world breakthroughs such as cochlear implants and the HPV vaccine. "We might be far away geographically, but our research excellence is outsized," she says. The opportunity now is to decide what Australia's next great contribution to global innovation will be.

Smarter investment, bringing together different sources of capital and sharing risk and responsibility, can turn Australia's research strengths into better health and new industries. Now is the time for the Australian Government to lead the development of a national health investment strategy, not alone, but in a blended model alongside industry, philanthropy, and domestic and international investors to turn that potential into lasting impact.